Thompson R L, Nakashizuka M, Stevens J G
Department of Microbiology and Immunology, UCLA School of Medicine 90024.
Microb Pathog. 1986 Aug;1(4):409-16. doi: 10.1016/0882-4010(86)90072-0.
We previously described a herpes simplex intertypic recombinant that is completely and specifically non-neurovirulent following intracranial inoculation. In this report the vaccine potential of this mutant (RE6) is analyzed. It is shown that RE6 replicates to wild type levels at the peripheral site of inoculation (the mouse footpad) but, unlike its virulent parental strains, does not replicate to detectable levels in lumbosacral ganglia. A single vaccination with RE6 is sufficient to completely protect mice against subsequent challenge with either HSV-1 or HSV-2. However, this agent establishes latent infections efficiently, and is fully neurovirulent for newborn mice.
我们之前描述过一种单纯疱疹病毒型间重组体，颅内接种后它完全且特异性地无神经毒性。在本报告中，对该突变体（RE6）的疫苗潜力进行了分析。结果显示，RE6在接种外周部位（小鼠足垫）可复制至野生型水平，但与其有致病性的亲代毒株不同，在腰骶神经节中无法复制到可检测水平。用RE6单次接种足以完全保护小鼠免受随后的HSV-1或HSV-2攻击。然而，该毒株能有效建立潜伏感染，且对新生小鼠具有完全的神经毒性。
